Who
Sheldon Sloan
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Spyre Therapeutics.
In numbers
- Trades disclosed
- 42
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $14.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Oct 2024
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $229K8,334 at $27.46 | filing |
| 1 Jul 2026filed 2 Jul 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $569K6,500 at $87.52 | filing |
| 1 Jul 2026filed 2 Jul 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K1,834 at $88.34 | filing |
| 1 Jul 2026filed 2 Jul 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,334 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,334 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $229K8,334 at $27.46 | filing |
| 1 Jul 2026filed 2 Jul 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $569K6,500 at $87.52 | filing |
| 1 Jul 2026filed 2 Jul 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $162K1,834 at $88.34 | filing |
| 3 Jun 2026filed 3 Jun 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $229K8,333 at $27.46 | filing |
| 3 Jun 2026filed 3 Jun 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $625K8,333 at $75.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,333 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,333 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $229K8,333 at $27.46 | filing |
| 3 Jun 2026filed 3 Jun 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $625K8,333 at $75.00 | filing |
| 1 May 2026filed 1 May 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $2.2M78,333 at $27.46 | filing |
| 1 May 2026filed 1 May 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M21,306 at $69.53 | filing |
| 1 May 2026filed 1 May 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M19,656 at $70.61 | filing |
| 1 May 2026filed 1 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —78,333 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $628K8,777 at $71.56 | filing |
| 1 May 2026filed 1 May 2026 | SYRE Spyre TherapeuticsBiotechnology | SEC FORM 4 Sold | $932K12,777 at $72.94 | filing |
News
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)SYRE · themarketsdaily.com · 19 Oct 2026Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026SYRE · manilatimes.net · 18 Oct 2026Spyre Therapeutics Shares Fall 13 Percent to $81 After Pricing a $350 Million Stock Offering at $85 a ShareSYRE · ibtimes.com.au · 6 Oct 2026
0 headlines in the last 90 days name Sheldon Sloan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.